Research programme: beta 3 adrenergic receptor agonists - Astellas PharmaAlternative Names: β3 adrenergic receptor agonists - Astellas Pharma
Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma
- Class Benzoic acids; Biphenyl compounds; Small molecules
- Mechanism of Action Beta 3 adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Overactive bladder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Overactive bladder in Japan (PO)
- 10 Apr 2008 Preclinical trials in Overactive bladder in Japan (PO)